Magnetic Fe$_3$O$_4$@graphene oxide improves the therapeutic effects of embryonic stem cells on acute liver damage

Tahereh Foroutan$^1$ | Mohammad Zaman Kassaee$^2$ | Mahdi Salari$^3$ | Fatemeh Ahmady$^1$ | Fatemeh Molavi$^1$ | Fariborz Moayer$^4$

1Department of Animal Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran
2Department of Organic Chemistry, Tarbiat Modares University, Tehran, Iran
3Department of Environmental Health Engineering, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
4Faculty of Veterinary Medicine, Islamic Azad University, Karaj, Iran

Correspondence
Tahereh Foroutan, Department of Animal Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
Email: foroutan@khu.ac.ir

Abstract

Objective: Acute liver failure is usually associated with inflammation and oxidation of hepatocytes and has high mortality and resource costs. Mesenchymal stem cell (MSCs) has occasionally been reported to have no beneficial effect due to poor transplantation and the survival of implanted cells. Recent studies showed that embryonic stem cell (ESC)-derived MSCs are an alternative for regenerative medicine. On the other hand, graphene-based nanostructures have proven useful in biomedicine. In this study, we investigated whether magnetic graphene oxide (MGO) improved the effects of ESC-MSC conditioned medium (CM) on protecting hepatocytes and stimulating the regeneration of damaged liver cells.

Materials and methods: To provide a rat model of acute liver failure, male rats were injected intraperitoneally with carbon tetrachloride (CCl$_4$). The rats were randomly divided into six groups, namely control, sham, CCl$_4$, ESC-MSC-CM, MGO and ESC-MSC-CM + MGO. In the experimental groups, the rats received, depending on the group, 2 ml/kg body weight CCl$_4$ and either ESC-MSC-CM with 5 $\times$ 10$^6$ MSCs or 300 $\mu$g/kg body weight MGO or both. Symptoms of acute liver failure appeared 4 days after the injection. All groups were compared and analysed both histologically and biochemically 4 days after the injection. Finally, the results of ESC-MSC-CM and MSC-CM were compared.

Results: The results indicated that the use of MGO enhanced the effect of ESC-MSC-CM on reducing necrosis, inflammation, aspartate transaminase, alanine aminotransferase and alkaline phosphatase in the CCl$_4$-induced liver failure of the rat model. Also, the expression of vascular endothelial growth factor and matrix metalloproteinase-9 (MMP-9) was significantly upregulated after treatment with MGO. Also, the results showed that the ESC-MSC-CM has more efficient effective compared to MSC-CM.

Conclusion: Magnetic graphene oxide improved the hepatoprotective effects of ESC-MSC-CM on acute liver damage, probably by suppressing necrosis, apoptosis and inflammation of hepatocytes.
1 | INTRODUCTION

Acute liver failure (ALF) is a life-threatening clinical syndrome characterized by rapid hepatocellular necrosis due to hepatotoxicity, viral infection and immune-mediated attacks. It has high mortality and resource costs. Liver transplantation has some limitations such as the lack of donors, costs and immunosuppressive complications. Mesenchymal stem cells (MSCs) have also been used to treat ALF. They are easy to obtain and do not pose an ethical problem. MSCs have functions such as secretion of growth factors, angiogenesis and immunosuppression, as well as properties such as anti-inflammatory and anti-apoptosis effects. They can also prevent hepatocyte cell death and stimulate the regeneration of liver cells by paracrine mechanism or direct differentiation.

In view of the ALF treatment with stem cells, the available data are somewhat contradictory. Although MSC injection has some benefits, it has occasionally been reported to have no beneficial effect due to poor transplantation and the survival of implanted cells. In addition, the failure of MSCs to adhere to the target tissue leads to apoptosis of MSCs. However, limitations to harvesting MSCs from adult tissue include the invasive procedures in most cases, availability of suitable donors, limited number of cells obtained during the harvesting process, and restricted in vitro expansion capacity. Recently, it has been shown that MSCs could be derived from ESC, with similar phenotypic characteristics, along with favourable immunomodulatory and anti-inflammatory properties that make them attractive candidates for regenerative medicine and they have been used to treat various animal models disease such as experimental autoimmune encephalitis.

On the other hand, administration of MSC-conditioned medium (ESC-MSC-CM) has been shown to improve tissue injury. The use of modern biotechnologies such as stem cells, laser and nanomaterial has attracted a great deal of attention in medical applications such as regenerative medicine. Graphene and its derivatives have been shown to improve the proliferation and differentiation of stem cells. Due to their physicochemical properties and biocompatibility, sometimes they act as natural extracellular matrices (ECM) and are able to regulate the differentiation of stem cells.

It has already been shown that the degree of cell differentiation and proliferation under different graphene oxide derivatives are different. For example, although in the absence of any osteogenic inducers the graphene nanogrids showed slight patterned osteogenic differentiations, the graphene sheets could not present any differentiation. On the other hands, the highly improvement of differentiation on the reduced graphene oxide nanoribbon grid was assigned to both its excellent effects on adsorption of the chemical osteogenic inducers and physical properties such as stresses oxidative.

Graphene oxide (GO) as a new class of carbon-based nanomaterials is a derivative of graphene with a two-dimensional honeycomb structure. The main difference between graphene and GO is the controllable hydrophilic nature of GO, which makes it well-dispersible in water. Because of its small size, ease of use and large specific surface area, GO has been recommended for biomedical applications such as biosensors, drug/gene delivery, and antibacterial effects. In addition, GO can absorb surface factors including proteins and small molecules, which are the essential components for the differentiation of MSCs. However, it is difficult to separate GO from the solution by conventional centrifugation and filtration methods as a result of its hydrophilicity, high dispersibility and small size.

Fe₃O₄ superparamagnetic nanoparticles are used in magnetically assisted drug delivery. They can easily be separated by a magnetic field. Nano composites based on magnetic graphene oxide (MGO) possess unique properties; they have high specific surface area, surface-active sites, excellent magnetic characteristics, high chemical stability, an adjustable size and shape, and can be simply functionalized or modified. The biocompatibility and anticancer effects of Fe₃O₄ in combination with graphene oxide have already been shown.

In this study, we investigated whether the synthesized MGO increases the protective effects of ESC-MSC-CM in the treatment of liver damage in animal models. We studied the possible in vivo hepatoprotective effects of MGO mixed with ESC-MSC-CM on the rat model of acute liver failure induced by carbon tetrachloride (CCl₄). CCl₄ is a well-known hepatotoxin and is often used to induce acute liver failure. The ability of ESC-MSC-CM mixed with MGO in the treatment of acute liver failure in rats was analysed by evaluating the serum level of enzymes and histopathological parameters.

2 | MATERIALS AND METHODS

In this study, the GO and magnetic GO were produced according to Hummers et al. and Kassaei et al. The GO prepared from graphite and the Fe₃O₄@GO composites were obtained by coprecipitation of FeCl₃·6H₂O and FeCl₂·4H₂O, in the presence of graphene oxide. The temperature was raised to 85°C, and ammonia solution was added for increasing the pH to 10. A mixture of styrene and benzoyl peroxide was added under a stream of N₂ in 10 min. The final mixture was homogenized by sonication at 0°C for another 30 min. Polymerization was carried out by increasing the temperature of the mixture in an oil bath to 80°C for 4 h under an inert nitrogen blanket.

2.1 | Characterization

GO and MGO were characterized by X-ray diffraction (XRD, Philips Xpert MPD, Co K radiation, = 1.78897A), Raman spectroscopy, scanning electron microscope (SEM, Philips XL30 microscope with an accelerating voltage of 25 kV), vibrating sample magnetometer (VSM), energy-dispersive X-ray spectroscopy (EDX), dynamic light scattering (DLS), Z potential and transmission electron microscopy (TEM) (PHILIPS, EM208S, Netherlands, at 100 kV of acceleration voltage).
2.1.1 Animals and experimental design

Syngeneic male Sprague-Dawley rats (220–280 g, Royan Institute) were kept under standard conditions in a light environment with temperature and humidity control. This study was approved by the Animal Care and Use Committee of the School of Biological Sciences at Kharazmi University. The acute liver damage model was obtained using a single intraperitoneal injection of 2 ml/kg body weight of CCl₄ dissolved in sterile olive oil (1:1). Human ESCs line RH6 obtained as gift maintained in an undifferentiated state on mitomycin C-treated mouse embryonic fibroblasts. Cells were subcultured on Matrigel-coated plates in ESC medium. The cells were passaged every 5 days. It was derived human ESC-MSC lines from RH6 ESC line, according to Hwang et al. protocol. To produce MSC-CM, passage-3 MSC cells were grown to 80% confluence cultured in a Dulbecco’s modified eagle’s medium supplemented with bovine serum albumin. MSC-CM was collected after 10 h.

The rats were divided into six groups, namely a control group receiving no treatment, a sham group injected with only olive oil, a group injected with CCl₄, a group injected with CCl₄ and 300 µg/kg body weight of MGO and a group injected with CCl₄, ESC-MSC-CM and 300 µg/kg body weight of MGO. All injections were intraperitoneal. For the sake of brevity, we refer to these groups as control, sham, CCl₄, ESC-MSC-CM, MGO and ESC-MSC-CM + MGO, respectively.

The number of rats in each group was n = 6. All animals received treatment on the first day. They were anaesthetized with ether 4 days after the intraperitoneal injection of CCl₄, ESC-MSC-CM and 300 µg/kg body weight of MGO. Blood samples were collected from the heart for biochemical analysis, and the livers were then taken for histological and immunostaining examination.

2.1.2 Quantification of serum biochemical

The blood samples were kept at room temperature for 1 h and then centrifuged at 1500 g for 12 min at 4°C. The serum was separated and kept at 20°C until analysis. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) were measured using an automated analyser (Hitachi) and commercially available kits (Pars Azmun) according to the manufacturer’s instructions.

2.1.3 Liver histology and immunohistology

The liver tissues were stained with haematoxylin–eosin (H&E) and observed with light microscopy (Zeiss). Primary mouse antibodies anti-MPO (1/100; Abcam), anti-CD68 monoclonal antibody (1:200; Serotec), anti-MMP-9 and anti-vascular endothelial growth factor (VEGF) were used to target neutrophils, Kupffer cells and liver regeneration-related proteins, respectively. Anti-TNF-α, anti-Caspase-3 and anti-IL-6 were also used to identify apoptosis and proinflammatory cytokines.

2.1.4 Vascular endothelial growth factor, TNF-α and IL-6 enzyme-linked immunoabsorbent assay

Serum levels of VEGF, TNF-α and IL-6 were measured by ELISA method. They were measured with ELISA Kits Rat VEGF (RVR00; R&D; Inc), Rat TNF-α (Dy510; R&D; Inc) and Rat IL-6 (R6000B; R7D; Inc).

2.1.5 Statistical analysis

The data were analysed using one-way analysis of variance for multiple comparisons. The significance level was set at p < 0.05 and p < 0.01. All data are expressed as means ± SE. Kolmogorov–Smirnov test was used to study normal distribution. Parametric continuous data with normal distribution between different groups were compared by one-way analysis of variance (ANOVA) followed by post hoc, Tukey test.

3 RESULTS

3.1 Synthesis of MGO nanohybrid

Scanning electron microscopy (SEM) image of typical morphological features is depicted in Figure 1. As seen, the as-prepared GO confirmed the synthesis of GO nanosheets with quite smooth surface, where the distinctive layered structure of the sample was evident. A sharp diffraction peak for the pristine graphite (2θ = 30.93°, index of 002, θ the Bragg angle, JCPDS No. 00-012-0212) is corresponding to a d-spacing of 0.337 nm. The observation is in consistent with the previous study. The as-prepared GO showed a characteristic peak at 2θ = 10.58° which resulted from the diffraction on its 002 layer together with a broad diffraction peak at 22.38°. Similar results have been reported in the previous study. The results for DLS and Zeta potential for pristine GO nanosheets and other nanoparticles analyses are given in Table 1.

Figure 1f displays the magnetic hysteresis curve of MGO to characterize the magnetic properties of the composite. The result emphasizes a great paramagnetic behaviour of MGO, showing a saturation magnetization of 44.7 emu/g.

Raman spectroscopy technique is applied to study structural characterization of carbon-based material. The structural changes during the chemical reactions of carbon-based material can be monitored by this technique. As seen in Figure 1g(a), Raman spectrum of graphite has obvious peaks displaying the D, G and 2D bands of graphite.

Figure 1(b) shows the Raman spectra of single-layer graphene oxide, displaying the G band at ~1580 cm⁻¹, the D band...
at \( \sim 1350 \text{ cm}^{-1} \) and the 2D band at \( \sim 2679 \text{ cm}^{-1} \). It is observed in Figure 1g(c) that in multi-layer graphene sheets, the position of the G shifts into lower wavenumbers and 2D bands shifts into higher wavenumbers.\(^{62,63}\) Figure 1g(b) also depicts the Raman spectrum of SMG composite. The position of bands shows no shift; however, the intensity of the bands has decreased. The similar result was found in the study conducted by Ning et al.\(^{64}\) The EDX analyses are given in Table 2.

### TABLE 1 Results for DLS and zeta potential for pristine GO nanosheets and other nanoparticles

| Sample        | Mean particle size (nm) | PDI   | Zeta potential (mV) |
|---------------|-------------------------|-------|---------------------|
| GO nanosheets | 456.9                   | 0.471 | \(-51.8\)           |
| MGO           | 584                     | 0.214 | 3.9                 |

### TABLE 2 EDX results for pristine GO nanosheets and the other nanohybrids

| Sample      | C (wt %) | O (wt %) | O/C  | Fe       |
|-------------|----------|----------|------|----------|
| GO nanosheets | 54.43   | 45.12    | 0.79 | -        |
| MGO         | 23.00    | 35.83    | 1.59 | 48.17    |

### 3.2 MGO inhibits the release of liver enzymes and improves survival rate

Our results indicated that treatment with MGO significantly improved the survival rate of CCl\(_4\)-induced liver failure in rats that received ESC-MSC-CM (Figure 2a). While only 20% of the rats survived for 35 days in the CCl\(_4\) group, 60% and 57% survived in the ESC-MSC-CM and MGO groups, respectively, and 100% survived.
during this period in the ESC-MSC-CM + MGO group. Liver damage was reduced in both ESC-MSC-CM and MSC-CM + MGO groups compared to the CCl₄ group 96 h after the injection. The recipients of ESC-MSC-CM + MGO developed liver dysfunction with significantly lower ALT, AST and ALP liver enzyme levels compared to the groups that received either ESC-MSC-CM or MGO (Figure 2b). Therefore, intraperitoneal injection of ESC-MSC-CM + MGO provided a significant survival benefit as it helped protect against liver damage and reduce mortality in recipient animals.

3.3 MGO injection improves histopathologic appearance and reduces neutrophil and Kupffer cell infiltration

We also examined the histopathologic changes in H&E and immunostained liver sections (Figures 3–6, Table 3). In the CCl₄ group, a significant increase in the number of neutrophil and Kupffer cells was found and compared to the control group. However, only a slight infiltration of inflammatory cell was observed in the ESC-MSC-CM + MGO group compared to the ESC-MSC-CM and MGO groups (Figures 3–6). The results indicated a significant reduction in the number of neutrophil and Kupffer cell infiltrations in the MGO and ESC-MSC-CM groups compared to the CCl₄ group (p < 0.01) (Figures 3, 4). In other words, the number of these cells in the ESC-MSC-CM + MGO group was lower than that in the MGO and ESC-MSC-CM groups (p < 0.01) (Figure 3a). The number of CD68 cells was also significantly lower in the ESC-MSC-CM + MGO group compared to other groups (Figure 3b). MPO-positive cells were also evident in all groups; however, the number of MPO-positive cells was significantly lower in the CCl₄ group after treatment with ESC-MSC-CM and MGO (p < 0.05) (Figure 3c). Treatment with MGO reduced the number of CD68 and MPO-positive cells in the CCl₄ESC-MSC-CM group significantly (p < 0.01). The results indicated that MGO improved the effects of ESC-MSC-CM on the treatment of damaged liver.

3.4 MGO lowers the level of proinflammatory cytokines and increases the expression of vascular endothelial growth factor and MMP-9 in damaged livers

In the CCl₄-induced livers, the expression levels of proinflammatory cytokines such as TNF-α, IL-6 and Caspase-3 decreased after MGO injection. Damaged livers stained with TNF-α, IL-6 and Caspase-3 antibodies showed that MGO injection inhibited apoptosis and necrosis of hepatocytes. Many apoptotic hepatocyte nuclei were observed in the CCl₄ group. Therefore, MGO promotes the survival of hepatocytes in the CCl₄ group. The levels of these cytokines were lower in the ESC-MSC-CM + MGO group than in the MGO and ESC-MSC-CM groups. Moreover, the expression of VEGF and MMP-9 was significantly upregulated after treatment with MGO (Figure 5). Also ELISA results showed a higher level of VEGF in...
MGO + ESC-MSC-CM compared with CCl4 group. On the other hand, higher levels of VEGF were found in MGO + ESC-MSC-CM compared with MGO and ESC-MSC-CM groups (Figure 7). ELISA results showed a higher level of VEGF in MGO + ESC-MSC-CM compared with CCl4 group. TNF-α and IL-6 expression were lower in the serum of rats receiving MGO compared with ESC-MSC-CM group (Figure 7).

4 | DISCUSSION

The ideal treatment for the CCl4-induced liver damage is to reduce symptoms such as apoptosis and inflammation and to promote immediate liver regeneration. In this study, we have shown that intraperitoneal injection of mixed with ESC-MSCs condition medium provides a significant survival benefit in rats, followed by a reduction in damage and serum enzymes. Previously, it has been reported that low doses of GO derivatives (3–8 mg/kg) showed no obvious clinical toxic signs. Since stem cell restoration of damaged organs is viewed as a paracrine effect rather than the direct effect of MSC entering into the organ, we studied the effects of hESC-MSC condition medium transplantation on the improvement of the damaged liver. Van Poll et al. and Parekkadan et al. showed that MSC-CM transplantation in rats with liver failure provides a significant survival benefit, as MSC-CM provides trophic support to the damaged liver by inhibiting hepatocellular death and stimulating regeneration. On the other hand, some studies have reported no survival benefit in animals treated with MSC-CM and ESC-MSC-CM. Lotfinia et al. reported, however, that while ESC-MSC and MSC-CM improved the function of the damaged liver, they did not increase survival. Several studies have shown antiapoptotic effects of MSC-CM on hepatocytes using in vitro and in vivo assays.

Some of the factors secreted from ESC-MSCs, such as vascular endothelial growth factor, have higher expressions compared to adult MSCs. VEGF is associated with biological processes such as regulation of epithelial cell proliferation and the immune system, as well as negative regulation of the apoptotic process. Our results showed that the expression of VEGF and MMP-9 was upregulated 48 h after the injection of the ESC-MSCs mixed with MGO. Since the addition of MGO to ESC-MSC-CM decreased the number of apoptotic cells, we propose that both chemokines, i.e., VEGF within ESC-MSC-CM and MGO, play a vital role in treating the damaged liver. Ma et al. showed that stem cells prevent liver apoptosis by secreting VEGF in vitro. They also showed that the ESC-MSC-CM is more effective compared to MSC-CM. Recently, various studies have shown that ESCs-MSCs possess more constant regenerative medicine effects, compared to adult MSCs. In other words, embryonic-MSC lines had consistently superior efficacy over MSCs derived from bone marrow samples. It could be correlated with the lower secretion of the IL6 from the ESCs-MSCs than from the adult-MSCs. They secrete more anti-inflammation and antiapoptosis factors, attenuating the inflammation and also cardiomyopathy symptoms. These results confirm the findings of Jiang et al. They showed that transplantation of ESC-MSCs has a stronger effect in organ regeneration than that of adult-MSCs.

However, we observed in our study that ESC-MSCs mixed with MGO exhibited better anti-inflammatory and anti-apoptosis properties in vivo than BM-MSCs, which may be due to the presence of highly expressed mediators in ESC-MSCs that included VEGF, MPO and MMP9. They have been shown to reduce inflammation or play a
FIGURE 5 Effects of MGO on the expression of VEGF and MMP-9 in the damaged livers treated with ESC-MSC-CM. MGO enhanced the number of VEGF and MMP-9-positive cells in the CCl4-induced livers treated by MSC-CM. Positive cells was visualized by VEGF and MMP-9 immunostaining in the liver sections 4 days after the injection. Scale bar, 200 μm (control, CCl4 + MGO and CCl4 + CM + MGO); scale bar, 400 μm (CCl4, CCl4 + CM). Abbreviations: CM, conditioned medium; CCL4, carbon tetrachloride; MGO, magnetic graphene oxide.

FIGURE 6 Treatment with ESC-MSC-CM + MGO after 3 days decreased the levels of proinflammatory cytokines IL-6 and Caspase-3 in liver failure induced by CCl4 compared to treatment with ESC-MSC-CM-MGO. Sections stained with H&E, IL-6 and Caspase-3. Abbreviations: CM, conditioned medium; CCl4, carbon tetrachloride; MGO, magnetic graphene oxide.

TABLE 3 Microscopic evaluation of hepatocytes in different treatment groups. Treatment with MGO improved the effects of ESC-MSC-CM on histopathologic appearance.

| Hyperemia | Accumulation of inflammatory cells | % Apoptosis | Average apoptotic cells per field | Sample         |
|-----------|-------------------------------------|-------------|----------------------------------|----------------|
| −         | −                                   | 0           | −                                | Control        |
| −         | −                                   | 0           | −                                | Sham           |
| +++       | +++                                 | 17.71       | 62                               | CCl4           |
| ++        | ++                                  | 5.90        | 19                               | MGO            |
| +         | +                                   | 8.32        | 29.8                             | ESC-MSC-CM     |
| ++        | ++                                  | 0.94        | 6                                | ESC-MSC-CM+MGO |

Note: −, +, ++, and +++ were used to assess hyperemia and accumulation of inflammatory cells and indicate no effect, slight, mild, and intensive, respectively.
central role in positive regulation of the immune system. Embryonic stem cells-MSCs are less mature than bone marrow MSCs, and its conditioned medium has higher paracrine factors with early embryogenesis and angiogenesis property than that by bone marrow-MSCs. The use of MGO was an effective way to enhance the therapeutic effects of stem cells condition medium. In this study, the positive effects of ESC-MSC-CM on the damaged tissue may be due to the physicochemical properties of S MGO or the improved delivery of growth factors within the stem cell medium to the damaged tissue. In other words, although the condition medium improved the survival and increased secretory proteins with trophic and immunomodulatory effects, its effects were less than those of MGO mixed with the medium. This could be due to the effects of the nanodeposition on the surface of trophic factors in serum followed by ECM protein absorption, which is essential for the adhesion, differentiation and growth of hepatocytes. Nevertheless, it could also be due to the capacity of MGO with condition medium to alter the migration of immune cell into the damaged liver.

In this work, we synthesized MGO and examined its role in increasing proliferation, angiogenesis and decreasing apoptosis in the damaged liver cells through the ability to bind and release growth factors. We proposed MGO nanoparticles as a new multifunctional target platform for effective delivery of biomolecules capable of treating damaged liver in vivo. We showed that GO in combination with Fe₃O₄ nanoparticles as biocompatible magnetic material accelerates the delivery of growth factors to the damaged tissue. One of the involved mechanisms is that graphene derivatives strongly adhered to macromolecules such as growth factors, which act as cell-adhesion substrate and growth factor-delivery carrier, thereby helps in the regeneration and improving damaged organs. On the other hand, ESC-MSCs induce a higher rate of hepatocyte proliferation and have stronger anti-inflammatory properties than bone marrow MSCs. Although MSC-CM and ESC-MSC improve liver function, they do not increase survival. Our results showed that MGO can improve the survival from CCl₄-induced liver failure in rats received ESC-MSC-CM.

5 | CONCLUSION

Our results indicated that MGO improved the effects of ESC-MSC-CM on the treatment of CCl₄-induced damaged livers. It inhibited liver parenchymal cell death and improved its regeneration through trophic support, thereby improving survival rate. In addition to stem cell therapy, stem cell modifications or MSCs in combination with other treatment methods are increasingly being considered. We concluded that in addition to transplanting ESC-MSC-CM and MSC-CM, liver damage can be synergistically treated by MGO through preventing apoptosis, enhancing angiogenesis and/or blocking the action of inflammatory factors. We concluded that MGO enhances the therapeutic effects
of secreted molecules of embryonic stem cell-derived mesenchymal stem cells on acute hepatic failure model.

ACKNOWLEDGEMENTS

We thank Dr. Elaheh Motamedi for technical assistance and data analysis.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS

Tahtereh Foroutan designed the study; Mohammad Zaman Kassae and Mehdi Salari performed most of nanomaterials experiments; Fatemeh Ahmadi and Fatemeh Molavi fed the animals and was involved in preparing of revised manuscript; and Fariborz Moayer assisted in histological study.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available within the manuscript or available from the authors upon request.

ORCID

Tahtereh Foroutan https://orcid.org/0000-0002-1476-3928

REFERENCES

1. Fu Y, Zheng S, Lin J, Ryser J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol. 2008;73:399–409.

2. Wang Y-H, Wu D-B, Chen B, Chen EQ. Progress in mesenchymal stem cell-based therapy for acute liver failure. Stem Cell Res Ther. 2018;9:227.

3. Saliba F, Samuel D. Acute liver failure, current trends. J Hepatol. 2013;59:6–8.

4. Volarevic V, Nurkovic J, Arsenijevic N, Stojkovic M. Concise review: therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis. Stem Cells. 2014;32:2818–2823.

5. Tao YC, Wang ML, Chen EQ, Tang H. Stem cells transplantation in the treatment of patients with liver failure. Curr Stem Cell Res Ther. 2018;13:193–201.

6. Du Z, Wei C, Cheng K, et al. Mesenchymal stem cell conditioned medium reduces liver injury and enhances regeneration in reduced-size rat liver transplantation. J Surgical Res. 2013;183:907–915.

7. Kopp JL, Grompe M, Sander M. Stem cells versus plasticity in liver and pancreas regeneration. Nature Cell Biol. 2016;3:238–245.

8. Li N, Zhang Q, Gao S, et al. Three-dimensional graphene foam as a biocompatible and conductive scaffold for neural stem cells. Sci Rep. 2013;3:1604.

9. Solanki A, Chueng ST, Yin PT, Kapper TR, Chhowalla M, Lee KB. Axonal alignment and enhanced neuronal differentiation of neural stem cells on graphene-nanoparticle hybrid structures. Adv Mater. 2013;25:5477.

10. Nayak TR, Andersen H, Makam VS, et al. Graphene for controlled and accelerated osteogenic differentiation of human mesenchymal stem cells. ACS Nano. 2011;5:4670.

11. Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon A. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein. Brain Res. 1986;387:271–280.

12. Lin F, Moran A, Garashi P. Intra renal cells not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. J Clin Invest. 2003;115:1756–1764.

13. Lin F, Cordes K, Li L, et al. Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol. 2003;14:1188–1199.

14. Park J, Kim B, Han J, et al. Graphene oxide flakes as a cellular adhesive: prevention of reactive oxygen species mediated death of implanted cells for cardiac repair. ACS Nano. 2013;5:1756–1764.

15. Lottinla M, Kadivar M, Piryea A, et al. Effects of secreted molecules of human embryonic stem cell-derived mesenchymal stem cells on acute hepatic failure model. Stem Cells Dev. 2016;25:1898–1908.

16. Gadkari R, Zhao L, Teklemariam T, Hantash BM. Human embryonic stem cell derived-mesenchymal stem cells: an alternative mesenchymal stem cell source for regenerative medicine therapy. Regen Med. 2014;9:453–465.

17. Sanchez L, Gutierrez-Arandana I, Ligero G, et al. Enrichment of human ESC-derived multipotent mesenchymal stem cells with immuno-suppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. Stem Cells. 2011;29:251–262.

18. Ferrer L, Kimbrel EA, Lam A, et al. Treatment of perianal fistulas with human embryonic stem cell-derived mesenchymal stem cells: a canine model of human fistulizing Cronh’s disease. Regen Med. 2016;11:33–43.

19. Wang X, Kimbrel EA, Ijichi K, et al. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Rep. 2014;3:115–130.

20. Van Poll D, Parekkadan B, Cho CH, et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology: 2008;47:1634–1643.

21. Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One. 2007;2:e941.

22. Paganelli A, Tarentini E, Benassi L, Kaleci S, Magnoni C. Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review. Clin Exp Dermatol. 2020;45(7):824–830.

23. Ayobian-Markazi N, Forootan T, Zhamtakhes A. An in vitro evaluation of the responses of human osteoblast-like SaOs-2 cells to SLA titanium surfaces irradiated by erbium, yttrium–aluminum–garnet [Er, YAG] lasers. Lasers Med Sci. 2014;29:47–53.

24. Foroutan T, Ahmadi F, Moayer F, Khalvati S. Effects of intraperitoneal injection of magnetic graphene oxide on the improvement of acute liver injury induced by CCl4. Biomater Res. 2020:24:14.

25. Foroutan T, Nafar M, Motamed E. Intraperitoneal injection of graphene oxide nanoparticle accelerates stem cell therapy effects on acute kidney injury. Stem Cells Cloning Adv Appl. 2020:13:21–32.

26. Eini F, Foroutan T, Bidadkosh A, et al. The effects of freeze/thawing process on cryopreserved equine umbilical cord blood-derived mesenchymal stem cells. Comp Clin Pathol. 2012;21:1713–1718.

27. Abedi A, Azamia M, Jamali Zavareh M, Foroutan T, Golestani S. Effect of different times of intraperitoneal injections of human bone marrow mesenchymal stem cell conditioned medium on gentamicin-induced acute kidney injury. Urol J. 2016;3:2707–2716.

28. Salehi PM, Foroutan T, Javari A, Taha MH. Extract of mouse embryonic stem cells induces the expression of pluripotency genes in human adipose tissue-derived stem cells. Iran J Basic Med Sci. 2018;20(11):1200.

29. Foroutan T, Amid R, Karimi MR. Comparison of manual tools, ultrasonic and erbium-doped yttrium aluminum garnet (Er: YAG) laser on the debridement effect of the surface of the root of teeth suffering from periodontitis. J Lasers Med Sci. 2013;4(4):199.

30. Abedini F, Foroutan T, Jahangiri L. Alkaline phosphatase and CD34 reaction of deciduous teeth pulp stem cells. Pak J Biol Sci. 2007;10(18):3146–3149.
31. Kim J, Park S, Kim YJ, et al. Monolayer graphene-directed growth and neuronal differentiation of mesenchymal stem cells. J Biomed Nanotechnol. 2015;11:1.

32. Akhavan O, Ghaderi E, Shalsavav M. Graphene nanogrids for selective and fast osteogenic differentiation of human mesenchymal stem cells. Carbon. 2013;59:200–211.

33. Lee WC, Lim CHYX, Shi H, et al. Origin of enhanced stem cell growth and differentiation on graphene and graphene oxide. ACS Nano. 2011;5(9):7334–7341.

34. Suo L, Dong X, Gao X, et al. Silica-coated magnetic graphene oxide nanocomposite based magnetic solid phase extraction of trace amounts of heavy metals in water samples prior to determination by inductively coupled plasma mass spectrometry. Microchem J. 2019:149.

35. Goncalves G, Vila M, Portoles M-T, Vallet-Regi M, Gracio J. Nano-grapheone, a potential multifunctional platform for cancer therapy. Adv Healthc Mater. 2013;2:1072–1090.

36. Greenwel P, Dominguez-Rosales JA, Mavi G, Rivas-Estilla M, Rokkind M. Hydrogen peroxide, a link between acetaldehyde-elicited alpha1(I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology. 2000;31:109–116.

37. Mohanty N, Berry V. Graphene-based single-bacterium resolution biodevice and DNA transistor: interfacing graphene derivatives with nanoscale and microscale biocomponents. Nano Lett. 2008;8(12):4469–4476.

38. Chiu NF, Kuo CT, Lin TL, et al. Ultra-high sensitivity of the non-immunological affinity of graphene oxide-peptide-based surface plasmon resonance biosensors to detect human chorionic gonadotropin. Biosens Bioelectrochem. 2017;94:351–357.

39. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through cmyb expression. J Clin Invest. 1995;96:2461–2468.

40. Arthur MJ, Mann DA, Iredale JP. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol. 1998;13:33–38.

41. Bao H, Pan Y, Ping Y, et al. Chitosan-functionalized graphene oxide as a nanocarrier for drug and gene delivery. Small. 2011;7:1569–1578.

42. Assali A, Akhavan O, Adeli M, et al. Multifunctional core-shell nanoplatforms (gold@graphene oxide) with mediated NIR thermal therapy to promote miRNA delivery. Nanomed Nanotechnol Biol Med. 2018;14(6):1891–1903.

43. Benyou RC, Arthur MJ. Mechanisms of hepatic fibrosis. J Pediatr Gastroenterol Nutr. 1998;27:75.

44. Akhavan O, Ghaderi E. Toxicity of graphene and graphene oxide nanowalls against bacteria. ACS Nano. 2010;4(10):5731–5736.

45. Liu S, Zeng TH, Hofmann M, et al. Antibacterial activity of graphite, graphite oxide, graphene oxide, and reduced graphene oxide: membrane and oxidative stress. ACS Nano. 2011;5(9):6971–6980.

46. Ryu S, Kim BS. Culture of neural cells and stem cells on graphene. Tissue Eng Regen Med. 2013;1:39.

47. Yoon HH, Bhang SH, Kim T, et al. Dual roles of graphene oxide in chondrogenic differentiation of adult stem cells, cell-adhesion substrate and growth factor-delivery carrier. Adv Funct Mater. 2014;24:6455.

48. Gonzalez-Rodriguez R, Campbell E, Naumov A. Multifunctional graphene oxide/iron oxide nanoparticles for magnetic targeted drug delivery dual magnetic resonance/ fluorescence imaging and cancer sensing. PLoS One. 2019;6:1–18.

49. Amirhassan A, Mehdi B, Eliey H. Poly [pyrrole-co-aniline] @ graphene oxide/Fe3O4 sorbent for the extraction and preconcentration of polycyclic aromatic hydrocarbons from water samples. New J Chem. 2018;42:16744–16751.

50. Liu M, Wen T, Wu X, et al. Synthesis of porous Fe3O4 hollow microspheres/graphene oxide composite for Cr [VI] removal. Dalton Trans. 2013;42:14710–14717.
71. Lian QZ, Zhang YL, Zhang JQ, et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation. 2010;121:1113–1191.

72. Takada Y, Hisamatsu T, Kamada N, et al. Monocyte chemoattractant protein-1 contributes to gut homeostasis and intestinal inflammation by composition of IL-10-producing regulatory macrophage subset. J Immunol. 2010;184:2671–2676.

73. Campbell E, Hassan MT, Pho C, et al. Graphene oxide as a multifunctional platform for intracellular delivery, imaging, and cancer sensing. Sci Rep. 2019;9:416.

74. Ahmad T, Rhee I, Hong S, et al. Ni-Fe$_2$O$_4$ nanoparticles as contrast agents for magnetic resonance imaging. J Nanosci Nanotech. 2011;11(7):5645–5650.

75. Seabra AB, Paula AJ, de Lima R, Alves OL, Duran N. Nanotoxicity of graphene and graphene oxide. Chem Res Toxicol. 2014;27:159–168.

76. Wang Y, Li Z, Wang J, Li J, Lin Y. Graphene and graphene oxide, biofunctionalization and applications in biotechnology. Trends Biotechnol. 2011;29:205–212.

77. Shadjou N, Hasanzadeh M, Khalilzadeh B. Graphene based scaffolds on bone tissue engineering. Bioengineered. 2018;9:38–47.

78. Justino CIL, Gomes AR, Freitas AC, et al. Graphene based sensors and biosensors. Trends Anal Chem. 2017;91:53–66.

79. Wettstein CM, Bonafe FP, Oviedo MB. Optical properties of graphene nanoflakes, shape matters. J Chem Phys. 2016;144:224305.

80. Hu W, Li Z, Yang J. Electronic and optical properties of graphene and graphitic ZnO nanocomposite structures. J Chem Phys. 2013;138:124706.

81. Crowdera SW, Prasaic D, Ratha R, et al. Three-dimensional graphene foams promote osteogenic differentiation of human mesenchymal stem cells. Nanoscale. 2013;5:4171–4176.

82. Kim TH, Lee T, El-Said WA, et al. Graphene-based materials for stem cell applications. Materials. 2015;8:8674–8690.

83. Ahmed MSU, Salam AB, Yates C, et al. Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer. Int J Nanomedicine. 2017;12:6973–6984.

84. Shen Z, Wu A, Chen X. Iron oxide nanoparticle based contrast agents for magnetic resonance imaging. Mol Pharm. 2017;14:1352–1364.

How to cite this article: Foroutan T, Kassaee MZ, Salari M, Ahmady F, Molavi F, Moayer F. Magnetic Fe$_3$O$_4$@graphene oxide improves the therapeutic effects of embryonic stem cells on acute liver damage. Cell Prolif. 2021;54:e13126. https://doi.org/10.1111/cpr.13126